Drug intelligence / Profile preview

glatiramer acetate + rituximab

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Intravenous

Overview

This is a combination therapy of glatiramer acetate and rituximab used in the treatment of multiple sclerosis. Glatiramer acetate is an immunomodulator that contains synthetic polypeptides of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) and works by modifying immune processes involved in multiple sclerosis pathogenesis. Rituximab is a monoclonal antibody that targets CD20-positive B cells. The combination has been studied particularly for secondary progressive multiple sclerosis (SPMS) and as an induction therapy approach for relapsing-remitting multiple sclerosis (RRMS).

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on glatiramer acetate + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glatiramer acetate + rituximab.

Explore the full profile